Literature DB >> 18708343

Prognostic factors and outcomes in patients with leptomeningeal melanomatosis.

Laura Harstad1, Kenneth R Hess, Morris D Groves.   

Abstract

The purpose of this study was to describe a cohort of patients with leptomeningeal melanomatosis (LM) and to determine prognostic factors for outcomes in these patients. The primary hypothesis was that more extensive burden of CNS metastasis at the time of diagnosis of LM (as evidenced by imaging of the CNS parenchyma and meninges and cerebrospinal fluid [CSF] cytology status [positive versus negative]) correlates with poorer outcomes. The records of all patients with LM treated at M. D. Anderson Cancer Center between 1944 and 2002 were reviewed. Information on clinical course and outcomes was gathered. Univariate and multivariate analyses were performed on 110 patients using Cox proportional hazards regression analysis to examine the effects of possible predictive factors on survival. The overall median survival from LM diagnosis was 10 weeks, with a 95% confidence interval (CI) of 8-14 weeks. Eighty-six (78.2%) patients had cutaneous primary lesions, and 23 (20.9%) had melanoma of unknown primary site. The primary hypothesis was not proven. Neither the presence of parenchymal CNS metastases, nor greater imaging evidence of LM, nor positive CSF cytology at diagnosis correlated with survival outcomes. Univariate analyses revealed possible predictors of longer survival, including the presence of supratentorial or spinal LM on imaging at diagnosis versus its absence and any treatment of LM, whereas elevated serum lactate dehydrogenase at the time of LM diagnosis predicted shorter survival. Multivariate analysis revealed that a history of a primary melanoma lesion originating on the trunk predicted shorter survival after LM diagnosis (hazard ratio [HR] = 2.0, 95% CI = 1.0-3.8, p = 0.035), and treatment with intrathecal chemotherapy predicted longer survival (HR = 0.5, 95% CI = 0.4-0.8, p = 0.0036). The positive result with respect to treatment is unreliable due to the inability to remove treatment selection bias from the analysis. This retrospective analysis confirmed the dismal prognosis associated with LM. The amount of CNS tumor burden at the time of diagnosis of LM did not inversely correlate with survival outcomes, contrary to our hypothesis.

Entities:  

Mesh:

Year:  2008        PMID: 18708343      PMCID: PMC2718998          DOI: 10.1215/15228517-2008-062

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  32 in total

1.  Leptomeningeal carcinomatosis. Presenting features and prognostic factors.

Authors:  M Balm; J Hammack
Journal:  Arch Neurol       Date:  1996-07

2.  Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease.

Authors:  C A Meyers; E A Obbens; R S Scheibel; R P Moser
Journal:  Cancer       Date:  1991-07-01       Impact factor: 6.860

Review 3.  Systemic treatments for advanced cutaneous melanoma.

Authors:  C M Anderson; A C Buzaid; S S Legha
Journal:  Oncology (Williston Park)       Date:  1995-11       Impact factor: 2.990

4.  Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

Authors:  J H Sampson; J H Carter; A H Friedman; H F Seigler
Journal:  J Neurosurg       Date:  1998-01       Impact factor: 5.115

5.  Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis.

Authors:  M N Sirott; D F Bajorin; G Y Wong; Y Tao; P B Chapman; M A Templeton; A N Houghton
Journal:  Cancer       Date:  1993-11-15       Impact factor: 6.860

6.  Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases.

Authors:  M C Chamberlain; P A Kormanik
Journal:  Arch Neurol       Date:  1997-11

7.  Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction.

Authors:  W E Samlowski; K J Park; R E Galinsky; J H Ward; G B Schumann
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-01

Review 8.  New aspects of immunotherapy of leptomeningeal metastasis.

Authors:  U Herrlinger; M Weller; M Schabet
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

9.  Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant.

Authors:  G C Jayson; A Howell; M Harris; G Morgenstern; J Chang; W D Ryder
Journal:  Cancer       Date:  1994-12-15       Impact factor: 6.860

10.  Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.

Authors:  K Fizazi; B Asselain; A Vincent-Salomon; M Jouve; V Dieras; T Palangie; P Beuzeboc; T Dorval; P Pouillart
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

View more
  42 in total

1.  Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab.

Authors:  I Bot; C U Blank; D Brandsma
Journal:  J Neurol       Date:  2012-04-18       Impact factor: 4.849

2.  Leptomeningeal metastasis from solid tumors: a diagnostic and therapeutic challenge.

Authors:  Maria Grazia Passarin; Teodoro Sava; Jenny Furlanetto; Annamaria Molino; Rolando Nortilli; Anna Maria Musso; Marta Zaninelli; Tiziano Franceschi; Daniele Orrico; Sabrina Marangoni; Cristina Dealis; Claudio Graiff; Rodella Filippo; Salvatore Grisanti; Edda Simoncini; Lucia Vassalli; Alfredo Berruti; Rebecca Pedersini
Journal:  Neurol Sci       Date:  2014-07-16       Impact factor: 3.307

3.  Two cases of primary leptomeningeal melanomatosis mimicking subacute meningitis.

Authors:  Sabina Aslan; Rahsan Gocmen; Nazire Pınar Acar; Farid Khasiyev; Ekim Gumeler; Figen Soylemezoglu; Aslı Tuncer; Ethem Murat Arsava; Mehmet Akif Topçuoglu; Isin Unal Cevik
Journal:  Neuroradiol J       Date:  2017-06-19

4.  Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance.

Authors:  Inna Smalley; Vincent Law; Clayton Wyatt; Brittany Evernden; Bin Fang; John M Koomen; Eric A Welsh; Robert J B Macaulay; Peter A Forsyth; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2020-01-10       Impact factor: 12.531

5.  Leptomeningeal metastases.

Authors:  Jordi Bruna; Marta Simó; Roser Velasco
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

6.  Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

Authors:  Sherise D Ferguson; Shivani Bindal; Roland L Bassett; Lauren E Haydu; Ian E McCutcheon; Amy B Heimberger; Jing Li; Barbara J O'Brien; Nandita Guha-Thakurta; Michael T Tetzlaff; Hussein Tawbi; Michael A Davies; Isabella C Glitza
Journal:  J Neurooncol       Date:  2019-03-07       Impact factor: 4.130

Review 7.  Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.

Authors:  Keiran S M Smalley; Inna V Fedorenko; Rajappa S Kenchappa; Solmaz Sahebjam; Peter A Forsyth
Journal:  Int J Cancer       Date:  2016-04-30       Impact factor: 7.396

8.  HSV-1 as a novel therapy for breast cancer meningeal metastases.

Authors:  D Kuruppu; K K Tanabe
Journal:  Cancer Gene Ther       Date:  2015-09-18       Impact factor: 5.987

9.  A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer.

Authors:  E Le Rhun; S Taillibert; F Zairi; N Kotecki; P Devos; A Mailliez; V Servent; L Vanlemmens; P Vennin; T Boulanger; M C Baranzelli; C André; G Marliot; J L Cazin; F Dubois; R Assaker; J Bonneterre; M C Chamberlain
Journal:  J Neurooncol       Date:  2013-03-01       Impact factor: 4.130

10.  Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report.

Authors:  Jee Min Lee; Urvi N Mehta; Ly H Dsouza; Beverly Ashleigh Guadagnolo; Deborah L Sanders; Kevin B Kim
Journal:  Melanoma Res       Date:  2013-04       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.